{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-008700","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.099636+00:00","generated_at":"2026-06-05T22:32:05.732706+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Ionis Q4 revenue $325M, up 114%; WAINUA approved; 2024 guidance: revenue >$575M","bullets":["Q4 total revenue $325M (up 114% YoY); full year revenue $788M (up 34%); Q4 operating loss narrowed to $6M from $208M.","WAINUA (eplontersen) FDA-approved for ATTRv-PN; U.S. launch underway; $50M milestone from AstraZeneca.","Positive Phase 3 data for olezarsen (FCS) and donidalorsen (HAE); preparing regulatory submissions.","2024 guidance: revenue >$575M, non-GAAP operating loss <$475M, cash ~$1.7B.","SPINRAZA royalties $240M in 2023; QALSODY royalties included; pipeline milestones with bepirovirsen, ION582."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-008700","json":"https://secwatch.observer/filing/0001140361-24-008700.json","markdown":"https://secwatch.observer/filing/0001140361-24-008700.md","text":"https://secwatch.observer/filing/0001140361-24-008700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036124008700/0001140361-24-008700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036124008700/ef20022046_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:32:05.732706+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}